Re: Prospective partners for ACH-1625 (or IDIX's compounds)
One wildcard in this discussion is MRK. Some knowledgeable people expect Boceprevir to fail in phase-3, either medically (from an excessive rate of anemia) or commercially (by simply not being as good as Telaprevir). If Boceprevir fails and MRK thinks its backup, MK-7009, is not the ticket, MRK could be in the hunt for another PI. Moreover, one would expect MRK to be interested in obtaining a non-PI oral drug to pair with Boceprevir, MK-7009, or an in-licensed PI. IDX184, INHX’s INX-189, and the early-stage compounds from VRUS would seem to fit the bill.
I had initially not considered MRK due to MK-7009. However, it looks like MK-7009 is strictly being tested as a BID drug, so if MRK (and for that matter all of the big pharma companies) is interested in qD dosing then ACH-1625 and IDX320 clearly would appear to be candidates.
I realize it's quite a stretch but I wonder if even VRTX would consider licensing a follow-on 2nd gen/3rd gen PI to Telaprevir to maintain their competitive edge down the road. Presumably that's an emphatic "no" now given that such a deal would make it look like VRTX doesn't have confidence in the longer-tem commercial outlook for Telaprevir.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.